Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

How Post PPV and ET Differ from Primary Myelofibrosis

Leuk Res; 2017 Jun 2; Masarova, Bose, Daver et al

Publish date:: June 25, 2017

Characteristics of post-polycythemia vera (PPV) and post-essential thrombocythemia (PET) myelofibrosis (MF) are very similar to primary MF (PMF), but outcomes differ, according to a study involving 755 individuals.

All participants had PMF and were referred to a single institution between 1984 and 2013. A subset had either PPV-MF (n=181) or PET-MF (n=163). Investigators compared clinical characteristics and outcomes. Among the results:

At a median follow-up of 31 months, 56% of patients had died.
Leukocytosis and systemic symptoms was highest in those with PPV-MF.
Thrombocytopenia was highest in patients with PMF and PPV-MF.
Median overall survival was 7 months in patients with PET-MF; it exceeded 40 months in the other 2 conditions.
Higher age, anemia, systemic symptoms, thrombocytopenia, and high peripheral blasts predicted inferior overall survival in PMF.
Age, anemia, and systemic symptoms predicted such for PPV-MF.
Anemia, peripheral blasts, and thrombocytopenia predicted it in PET-MF.

Citation:

Masarova L, Bose P, Daver N, et al. Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis. Leuk Res. 2017;59:110-116. doi:10.1016/j.leukres.2017.06.001.

This Week's Must Reads

Consider potential cognitive complications prior to androgen deprivation therapy,

Diabetes raises risk of prostate cancer mortality in obese men,

Salivation inhibition fails to reduce radioiodine toxicity in prostate cancer,

Highest positive surgical margin predicts poor survival after prostatectomy,

Young minority men are underinformed about prostate cancer screening,

Must Reads in Hematologic Malignancies

Long-term ibrutinib data in older patients, Barr PM et al. Haematologica. 2018;103(9):1502-10

Prognostic Score System for Patients with PMF, J Clin Oncol; ePub 2017 Dec 9; Gugliemelli, et al

These Patients Are More Apt to Be Depressed, Ann Hematol; ePub 2017 Dec 7; Shreders, et al

Survival Length Shortest in These Patients with MF, Eur J Haematol; ePub 2017 Dec 11; Masarova, et al

The Value of Ruxolitinib Before and After AlloSCT, Blood; ePub 2017 Dec 7; Poulose, Malysz, et al